p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant by Humpton, Timothy J. et al.
Humpton et al. Cancer & Metabolism            (2018) 6:18 
https://doi.org/10.1186/s40170-018-0191-6RAPID COMMUNICATION Open Accessp53-mediated adaptation to serine
starvation is retained by a common
tumour-derived mutant
Timothy J. Humpton1†, Andreas K. Hock1†, Oliver D. K. Maddocks3 and Karen H. Vousden2*Abstract
Background: In response to oncogenic stress, the tumour suppressor protein p53 can induce the elimination of
cells through induction of cell death or senescence, helping to restrain malignant progression. Conversely, under
nutrient stress, p53 can protect cells by supporting metabolic adaptation. Many cancers express mutant p53
proteins that have lost the cell-elimination properties of wild-type p53. However, a previous report showed that a
tumour-derived mutant can retain the ability to support cells under glutamine starvation.
Results: We show that a commonly occurring p53 mutant, R248W, retains wild-type ability to support survival
under serine starvation. R248W, but not R175H, can engage p21 and MDM2, which both function to limit oxidative
stress and facilitate the switch to de novo serine synthesis. In vivo, the growth of R248W-expressing tumours is
resistant to dietary depletion of serine and glycine, correlating with an increased capacity to limit ROS compared to
tumours expressing R175H. Human cancers expressing this p53 mutant show a worse outcome.
Conclusion: Our work shows that mutant p53s can selectively retain wild-type p53 functions that allow adaptation
to serine starvation through the activation of antioxidant defence pathways. Tumours containing this p53 mutation
are resistant to serine-limited conditions and less responsive to therapy.
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The p53 protein plays an important role as a tumour sup-
pressor, with loss of wild-type p53 activity evident in many
human tumours [1]. The importance of p53’s tumour sup-
pressor role is demonstrated by the consequences of
germline loss or mutation of p53, which lead to early
tumour development in both humans and mice [2, 3].
Functioning as a transcription factor, p53 regulates a com-
plex network of gene expression that leads to the activa-
tion of a variety of responses, including both cell survival
and cell elimination [4]. These different and opposing
functions of p53 have been rationalised in a model where
p53 responds to transient metabolic stress by supporting
cell survival and repair, while more severe damage or per-
sistent stress promotes p53 responses that eliminate the
affected cell [5]. Of note, however, the survival activities of* Correspondence: karen.vousden@crick.ac.uk
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stress, and this activity has been linked to increased
tumourigenicity and resistance to therapy [6, 7].
Many tumour-associated p53 mutations lead to the ex-
pression of full-length p53 proteins carrying single
amino acid substitutions, which are generally clustered
in the DNA-binding domain of the p53 protein. While
almost every amino acid in this region has been found
mutated in cancer, a few “hotspot” codons are more fre-
quently mutated, with substitutions of three residues in
particular (R175, R248, and R273) accounting for over
15% of p53 mutations across all tumour types [8]. Inter-
estingly, substitutions of amino acids at these residues
have different effects on the overall structure of p53.
R248 and R273 are both residues of p53 that directly
contact DNA and mutations at these sites (most com-
monly R248Q, R248W, R273H, and R273C) lower the
affinity of p53 to DNA and thus impede its transcrip-
tional activity [9]. Residue R175 is not at a DNA contact
site, but substitutions at this residue (most commonlyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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p53 protein, again inhibiting DNA binding to consensus
p53 response elements [9]. Overall, therefore, these mu-
tations lead to a loss of wild-type p53 function. However,
comparison of p53-null and mutant p53 expressing tu-
mours has shown that the expression of mutant p53 can
result in a gain of function, leading to a more aggressive
phenotype [10, 11] generally associated with an en-
hanced ability to promote invasion and metastasis [12].
Notably, these “gain of function” properties are not gen-
erally exhibited by wild-type p53.
In light of the observation that wild-type p53 can func-
tion to support cells under nutrient starvation and that
this activity of p53 can support tumour development, we
considered the possibility that some mutant p53s may
retain the pro-survival activities of wild-type p53 while
concomitantly losing the cell elimination functions. We
showed previously that wild-type p53 can support the
adaptation of cells to serine and glycine starvation by ac-
tivating the expression of p21, so diverting limiting
serine to the synthesis of glutathione for antioxidant de-
fence, rather than to nucleotide synthesis [13]. Another
transcriptional target of p53, MDM2, was also shown to
help cells under serine starvation by cooperating with
ATF4 in the activation of the de novo serine synthesis
pathway genes [14]. It is therefore of interest to note
that some tumour-derived p53 mutants retain some
wild-type transcriptional activity, and interestingly, a re-
cent study has reported cancer cell survival activities of
mutant p53 under glutamine starvation that reflected an
ability to induce the expression of p21 [15].
Methods
Cell culture
Parental HCT116 cells were purchased from ATCC.
HCT116 p53 KO clones and p53 KO clones stably ex-
pressing p53 mutants R175H, R248W, and R273H were
created using CRISPR/Cas9 and subsequent infection
with pWZL-p53mut-BLAST and pBabe-iRFP-PURO
plasmids as previously described [16]. Stock flasks of all
cells were maintained in McCoy’s 5A (modified) medium
(Gibco, 26600023) supplemented with 10% FBS and 1%
penicillin-streptomycin. All cells were cultured at 37 °C
in a humidified atmosphere of 5% CO2.
Serine and glycine deprivation
Serine and glycine deprivation experiments were conducted
as previously described [13]. Briefly, cells were seeded and
left for 24 h in Dulbecco’s modified Eagle medium
(DMEM) (Gibco, 21969) supplemented with 10% FBS and
2 mM L-glutamine. The medium was then changed daily
either continuing with the seed DMEM (full medium
conditions) or switching to starvation medium (− SG).
The − SG medium consisted of MEM (21090)supplemented with additional 1× MEM vitamins (Gibco,
11120), 10% dialysed-FBS (Hyclone, Thermo Scientific),
2 mM L-glutamine, and additional D-glucose (to 25 mM).Growth curves
For counting, cells were seeded in 24-well plates in full
medium. The next day, cells were shifted to serine- and
glycine-depleted medium or given fresh full medium.
Medium was replaced every day. For counting, cells were
trypsinized, re-suspended in PBS-EDTA, and counted with
a CASY Model TT Cell Counter (Innovatis, Roche Applied
Science) at the indicated time points in each experiment.
Cell counts were conducted prior to any media change.
Measuring cell growth using iRFP was performed as
previously described [17]. Briefly, cells were seeded in
96-well CellBIND black microplates with clear flat bot-
tom (Corning 3340) and allowed to settle. The next day,
cells were shifted to serine- and glycine-depleted
medium or given fresh full medium. Media were re-
placed daily. iRFP intensity was measured using an
Odyssey Li-Cor. For quantification, plates were scanned
at 169 μm resolution with a 3.5-mm offset and a
low-intensity setting held constant throughout each ex-
periment. Image Studio software (LI-COR, V5.2) was
used to scan and subsequently quantify the plates.Flow cytometry
Adherent cells were labelled with CellROX Green reagent
(5 μM) for 15 min in serum-free and phenol-red-free
DMEM (C10444, Life Technologies). Cells were then
washed in phosphate buffered saline (PBS) and
re-suspended in 1x PBS+ 2%FBS for analysis. 4′,6-Diami-
dino-2-phenylindole dihydrochloride (DAPI, Sigma Al-
drich) was added to a final concentration of 1 μg/ml to
each sample and was used to identify viable cells for ana-
lysis. Single cells were analysed on a BD Fortessa flow cyt-
ometer using unstained and cumene hydroperoxide-
stained (100 μM) cells as controls. At least 10,000 events
were collected for each sample. Data were analysed using
FlowJo X 10.0.7r2 (FlowJo, LLC). Unless otherwise stated,
median fluorescence intensity values were obtained and
compared across samples.siRNA transfection
The siRNA used to target humanMDM2, p21 (CDKN1A),
and ATF4, as well as the non-targeting siRNA control
pool, were all purchased from Dharmacon (siGENOME
SMART pool siRNA) and transfected at 20 nM concentra-
tion using Lullaby siRNA transfection reagent and the
manufacturer’s recommended reverse transfection proced-
ure (OZ Biosciences). Cells were left in the seeding/trans-
fection medium for 24 h prior to any medium change.
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Liquid chromatography-mass spectrometry (LC-MS)
sample preparation and analysis were performed broadly
as described previously [18, 19]. Cells were incubated in
fresh assay medium for 3 h. Metabolites were extracted
by rapidly removing cell media, washing wells once with
ice-cold PBS, and lysing cells in ice-cold methanol/
acetonitrile/H2O (50:30:20) at volumes scaled based on
cell counts of the counting plate to 2 × 106 cells per
millilitre extraction buffer. Sample plates were shaken at
4 °C for 10 min before the extraction buffer was col-
lected from each well, spun for 15 min at 16,000×g in a
chilled (4 °C) centrifuge, and then analysed by LC-MS.
For metabolite analysis, a Q Exactive Orbitrap mass
spectrometer (Thermo Scientific, Waltham, MA, USA)
was used together with a Thermo Ultimate 3000 HPLC
system. The HPLC setup consisted of a ZIC-pHILIC col-
umn (SeQuant, 150 × 2.1 mm, 5 μm, Merck KGaA,
Darmstadt, Germany), with a ZIC-pHILIC guard column
(SeQuant, 20 × 2.1 mm) and an initial mobile phase of
20% 20 mM ammonium carbonate, pH 9.4, and 80%
acetonitrile. Cell and media extracts (5 μl) were injected,
and metabolites were separated over a 15-min mobile
phase gradient, decreasing the acetonitrile content to
20%, at a flow rate of 200 μl/min and a column
temperature of 45 °C. The total analysis time was
23 mins. All metabolites were detected across a mass
range of 75–1000 m/z using the Q Exactive mass spec-
trometer at a resolution of 35,000 (at 200 m/z), with
electrospray (ESI) ionisation and polarity switching to
enable both positive and negative ions to be determined
in the same run. Lock masses were used, and the mass
accuracy obtained for all metabolites was below 5 ppm.
Data were acquired with Thermo Xcalibur software. The
peak areas of different metabolites were determined
using Thermo TraceFinder 4.0 software where metabo-
lites were identified by the exact mass of the singly
charged ion and by known retention time on the HPLC
column. Commercial standards of all metabolites de-
tected had been analysed previously on this LC-MS sys-
tem with the pHILIC column.
Immunoprecipitation
For the analysis of p53 conformation, IP experiments were
performed broadly as previously described [20]. Adherent
cells were washed once in ice-cold PBS. Protein lysates
were then prepared using RIPA buffer (Millipore) supple-
mented with cOmplete ULTRA EDTA-free protease in-
hibitors (Roche) and PhosSTOP phosphatase inhibitors
(Roche). Equivalent amounts of total protein (1.5–2 μg),
determined using a Pierce BCA protein assay kit (Ther-
moFisher Scientific), were incubated overnight at 4 °C
with either p53 Ab1620 (Abcam) or pAb240 (Santa Cruz
Biotechnology) antibody (1:100 dilution) and 20 μl ofProtein G Dynabeads (ThermoFisher Scientific). Beads
were washed three times in RIPA and resuspended in buf-
fer containing RIPA, NuPAGE LDS sample buffer, and
NuPage Reducing Agent (both ThermoFisher Scientific).
Protein was eluted from the beads by boiling at 95 °C for
10 min. The resulting samples were analysed by Western
blotting.
For ATF4 IP experiments, samples were prepared as de-
scribed above except they were incubated with ATF4 anti-
body D4B8 (Cell Signaling Technology) (1:100 dilution)
instead of the p53 antibodies.
Western blotting
As with the IP experiments, protein lysates were prepared
using RIPA buffer (Millipore) supplemented with cOmplete
ULTRA EDTA-free protease inhibitors (Roche) and
PhosSTOP phosphatase inhibitors (Roche). The resulting
samples were separated using precast NuPAGE 4–12%
Bis-Tris protein gels (ThermoFisher Scientific), transferred
to nitrocellulose membranes using NuPAGE transfer buffer
(ThermoFisher Scientific) with 20% methanol, and blocked
in a PBS solution containing 5% BSA (Sigma Aldrich) and
Tween-20 (Sigma Aldrich). Membranes were incubated
overnight at 4 °C with primary antibodies (1:1000 dilution
unless otherwise indicated). Membranes were washed in
PBS-Tween20 and incubated with secondary antibodies
(1:15000 dilution) for 45 min at room temperature prior to
a final set of washes in PBS (no Tween 20) and detection.
Proteins were detected using a Li-Cor Odyssey Infrared
Scanner and LiCor Image Studio Software.
Primary antibodies
MDM2 (SMP-14) (sc-965), MDM2 (D-7)(sc-13161),
CREB-2 (B-3)(sc-390063), p53 (DO-1) (sc-126), PSPH
(H-11)(sc-365183), PSAT1 (L-24)(sc-133929), p53 (pAb240)
(sc-99), and Actin (I-19)(sc-1616) were purchased from
Santa Cruz Biotechnology.
The p53 (pAb1620) (ab16776) was purchased from
Abcam.
COXIV (#11967), HSP90 (#4877), p21 (#2947),
PHGDH (#66350), ATF4 (#11815), and HA-tag (#3724)
were purchased from Cell Signaling Technology.
Secondary antibodies
IRDye 800CW and 680LT all raised in Donkey (anti-Goat,
anti-Rabbit, and anti-Mouse) were used for standard
Western blots (LiCor).
Light chain-specific monoclonal antibodies with AF
680 or AF790 probes were used for IP Western blots
(Jackson ImmunoResearch).
Animal experiments
Mouse procedures were carried out under UK Home Office
licence number 60/4181 (Karen Blyth) and conducted in
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the EU Directive 2010. Experiments were sanctioned by
Local Ethical Review Process (University of Glasgow). Mice
were housed on a 12/12 light/dark cycle and fed and
watered ad libitum.
For HCT116 xenograft experiments, athymic female
nude (nu/nu) mice (obtained from The Jackson Laboratory,
7–8 weeks old) were fed specified diets either containing or
lacking serine and glycine as previously described [13, 21]
for a period of 1 week prior to the start of the experiment.
Mice in each group received bilateral subcutaneous injec-
tions of 100 μl of either HCT116 R175H or R248W cells
(2 × 106 cells) suspended in phosphate buffered saline (PBS)
(n = 5 mice per group). Each mouse was injected with only
one cell line. Following injection, subcutaneous tumour
growth was monitored by both iRFP imaging as previously
described [22] and using callipers (both twice per week).
Relative tumour growth was determined by comparing
iRFP intensity to the baseline (day 3 post-injection) scan for
each tumour. Tumour volume by callipers was calculated
using the formula (length ×width2/2).
Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin for
24 h before paraffin embedding and sectioning. Slides
cut from paraffin blocks were de-paraffinised and rehy-
drated. Antigen retrieval was performed in citrate-based
antigen unmasking solution (Vector H-3300) for 15 min
in a microwave. Endogenous peroxidase activity was
quenched by incubation with BLOXALL blocking solu-
tion (Vector SP-6000) according to the manufacturer’s
instructions. For p21 and MDA staining, slides were
blocked in 5% BSA with 5% rabbit serum in TBS-T for
1 h. Slides were incubated with primary antibody diluted
to 1:1000 in blocking solution overnight at 4 °C.
Secondary antibody incubation and downstream signal
detection were performed using the Vectastain ABC elite
kit (Vector PK-6010) and ImmPACT DAB (Vector
SK-4105) following the manufacturer’s recommenda-
tions. For MDM2 IHC staining, slides were instead proc-
essed using the M.O.M. kit and protocol from Vector
Labs (BMK-2202) with the primary antibody diluted to
1:1000. Slides were dehydrated, counterstained, and
mounted with coverslips prior to analysis using Olympus
BX51 microscope.
IHC quantification
Seven random × 20 magnification images were taken
from each IHC slide using an Olympus BX51 micro-
scope with Zen Blue software (Zeiss). From these im-
ages, the positive staining per slide area was calculated
using ImageJ software. Each image was expanded into
an RGB stack with the green channel used for quantifi-
cation as it offered the best separation for DAB staining.For each set of stained slides, a control slide was used to
set a threshold for positive staining. This threshold was
then applied in batch format to the rest of the images in
the set (all images from all slides stained with a given anti-
body), and the resulting positive staining area for each was
measured and collected by ImageJ. These measured areas
were then averaged across the images of a given slide to
give a staining percentage area value for each sample.
Human patient survival analysis
We obtained survival data by accessing the publicly
available harmonised cancer datasets hosted on the Na-
tional Cancer Institute GDC data portal. Through the
portal, we compared survival between patients with
R248 mutations (either R248W or R248Q) to those with
the R175H mutation. Patient survival data arising from
this search were imported into GraphPad Prism. The
median survival of each group was compared using the
Mantel-Cox Log-rank test.
Data plotting and statistical analysis
All data were plotted using Prism 7 (Graph Pad). Statis-
tical analysis for each experiment was performed using
the tools within Prism 7 and the indicated tests.
Results
Based on our previous observations showing a role for
wild-type p53 in the adaptation to serine and glycine
deprivation [13], we expanded our analysis to determine
whether common p53 mutant alleles also retain the abil-
ity to support cells under serine and glycine starvation.
A previously described series of HCT116 cells (a human
colorectal tumour line) that express wild-type p53, no
p53, or the R248W p53 mutant [23] are complicated by
potential activity arising from high levels of expression
of a smaller p53 isoform in the line deleted for
full-length p53 [24, 25]. To avoid this issue and to de-
velop a model in which additional p53 mutants could be
examined, we used gene editing to produce a p53 null line
that lacked any detectable p53 expression and then
reintroduced ectopic expression of three common p53
mutants —R175H, R248W, and R273H. As seen in human
cancers [26], the mutant forms of p53 were expressed at
higher levels than the endogenous wild-type p53 (Fig. 1a).
The R175H mutation has been reported to drive a con-
formational shift in the p53 protein, while R248W and
R273H alter DNA-contacting residues and retain a
predominantly wild-type conformation [27, 28]. Using
conformation-specific antibodies, we were able to confirm
that in our engineered cells, the R175H mutant adopts an
unfolded or mutant conformation (detected by Ab240)
while the R248W and R273H mutants remained mostly in
a wild-type conformation (detected by Ab1620) (Fig. 1b).
The retention of the wild-type conformation by R248W
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Fig. 1 The R248W mutant retains wild-type ability to engage p21 and MDM2 and promotes adaptation to serine and glycine (SG) deprivation. a
Western blot for p53 in HCT116 cells with parental WT p53 (WT), CRISPR-mediated p53 deletion (KO), or p53 KO cells reconstituted with mutant p53
expression constructs R175H, R248W, or R273H (175, 248, 273). HSP90 expression used as a loading control. b p53 protein in wild-type (IP by pAB1620)
and mutant/unfolded (IP by pAb240) conformation in the indicated cell lines, detected by immunoprecipitation followed by Western blot. c Western
blot for p53, MDM2, and p21 in the indicated cell lines treated with the MDM2 inhibitor RG7388 (+) (5 μM) or DMSO vehicle control (−) for 24 h. d The
indicated cell lines were cultured in full medium, full medium containing the MDM2 inhibitor nutlin-3A (10 μM), or SG-depleted medium for 8 days. e
Cell counts of the indicated cell lines cultured in full medium, full medium containing the MDM2 inhibitor nutlin-3A (10 μM), or SG-depleted medium
for 8 days. Data are represented as the mean of triplicate wells ± SEM for each condition. f Western blot for MDM2 and p21 in the indicated cell lines
cultured in full medium (day 0) before being switched to grow in SG-depleted medium for 1 or 2 days. Note: this blot was re-probed for PSAT-1 and
PSPH and shown in Fig. 2c. The ACTIN loading control blot is therefore the same in both figures
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p53s retained any ability to induce the expression of ca-
nonical p53 target genes. Although the basal levels of the
mutant p53 proteins were higher than that of the
wild-type p53, all p53 proteins were somewhat stabilised
in response to treatment with the MDM2 inhibitor
RG7388 [29], reflecting an ability of MDM2 to target both
wild-type and mutant p53s for degradation [30, 31]. This
stabilisation was accompanied by increased expression of
two canonical p53 target genes, p21 and MDM2, in both
wild-type p53 and R248W-expressing cells, although this
response was not seen in R175H- or R273H- expressing
cells (Fig. 1c).
Proliferation assays in normal medium showed a simi-
lar growth rate for each of these cell lines, regardless of
p53 status (Fig. 1d, e). Activation of p53 using the
MDM2 inhibitor nutlin-3A blocked proliferation in the
wild-type p53-expressing cells, but not the p53 null or
R248W cells (Fig. 1d, e), despite the induction of clearly
detectable levels of p21 in the R248W cells. However,
the p53 null cells were more sensitive than wild-type
p53 cells to removal of serine and glycine from the
growth medium, confirming previous observations [13].
Interestingly, cells expressing R248W retained the abil-
ity to proliferate in serine- and glycine-free medium
while R175H-expressing cells were less able to adapt to
these conditions, behaving comparably to p53 null cells
(Fig. 1d, e). Further analysis of the previously published
HCT116 cell lines confirmed the ability of R248W to
function like wild-type p53 in supporting proliferation in
the absence of serine and glycine (Additional file 1:
Figure S1A). Importantly, serine and glycine starvation in-
duced p53 activity, as measured by the induction of p21
and MDM2 expression, in both the wild-type p53 and
R248W cells, but not p53 null or R175H cells (Fig. 1f).
Previous studies have shown that both p21 and MDM2
can contribute to the ability of cells to adapt to serine star-
vation [13, 14]. Consistently, siRNA-mediated depletion of
p21 inhibited the proliferation of wild-type p53 and
R248W-expressing cells under serine and glycine starva-
tion without impacting the growth of these cells in fully
fed conditions (Fig. 2a and Additional file 1: Figure S2A).
In full medium, depletion of MDM2 in wild-type p53 cells
inhibited growth through stabilization of p53, while
MDM2 inhibition did not impact the growth of R248W
expressing cells (Fig. 1c) under these conditions. However,
depletion of MDM2 strongly decreased the growth of
R248W cells (Fig. 2b and Additional file 1: Figure S2B) in
serine- and glycine-free medium, consistent with a role for
MDM2 in allowing the adaptation of these cells to loss of
exogenous serine and glycine.
Previous studies have shown that during serine starva-
tion, MDM2 drives the expression of the serine synthesis
pathway enzymes through interaction with ATF4 [14],so facilitating proliferation. We therefore considered
whether the lack of induction of MDM2 in p53 null or
R175H-expressing cells may hinder the upregulation of
the serine synthesis pathway (SSP). As expected, expres-
sion of PSAT-1 and PSPH were efficiently activated in
response to serine starvation in p53 wild type and
R248W cells (Fig. 2c). However, equally efficient induc-
tion of these SSP genes was also seen in p53 null and
R175H cells (Fig. 2c). As already shown, p53 null and
R175H cells expressed lower levels of MDM2 that was
not induced by serine starvation. However, directly de-
pleting cells of MDM2 using siRNA substantially inhib-
ited the increased expression of PHGDH, PSAT-1, and
PSPH in both p53 null and R248W cells (Fig. 2d) under
serine starvation. These results support the importance
of MDM2 in allowing activation of the SSP but suggest
that even the low levels of MDM2 retained in p53 null
cells are sufficient for this activity.
In order to assess whether the p53-dependent differ-
ences in MDM2 levels seen in the cell lines contribute
to the ability of these cells to proliferate in the absence
of exogenous serine, we introduced a plasmid to express
MDM2 into p53 null cells. In this system, ectopic
MDM2 expression did not affect the growth rate of cells
in fully fed conditions, but clearly supported enhanced
proliferation under serine and glycine starvation (Fig. 2e,
f and Additional file 1: Figure S2C). In contrast, ectopic
expression of MDM2 in cells containing wild-type p53 did
not further increase their ability to adapt to serine and gly-
cine starvation (Additional file 1: Figure S2D). Taken to-
gether, the data suggest that the p53-dependent increase
in MDM2 above basal levels seen in wild-type p53 and
R248W cells contributes to their ability to adapt to serine
and glycine starvation through a mechanism that is dis-
tinct from the requirement for MDM2 to induce the SSP.
We next considered whether other consequences of
the MDM2/ATF4 interaction may be contributing to the
ability of increased MDM2 to protect cells under serine
and glycine starvation. Previous work demonstrated the
importance of ROS limitation when cells are serine
starved [13], and ATF4 has been shown to play a role in
supporting an antioxidant response [32–34]. R248W
cells showed a trend towards lower ROS levels than
R175H cells in full medium and were able to limit ROS
accumulation more efficiently than R175H cells under
serine and glycine starvation (Fig. 3a). However, this
ability of R248W cells to limit ROS accumulation upon
serine/glycine starvation was lost following depletion of
MDM2 (Fig. 3a). Conversely, overexpression of MDM2
in p53 null cells substantially prevented the elevation in
ROS levels seen following serine and glycine starvation
(Fig. 3b). Consistent with this observation, R248W cells
maintained a more reduced NADPH/NADP+ ratio than
p53 null cells under both fully fed and serine and glycine
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Fig. 2 Augmented expression of p21 and MDM2 during serine and glycine (SG)-deprivation promotes adaptation in R248W cells independently
of MDM2-facilitated SSP induction. a Growth of the indicated cell lines treated with non-targeting control or p21 siRNA and cultured in SG-
depleted medium for 7 days. iRFP intensity in each well on day 7 (top) and iRFP level per well relative to the day 2 reading (bottom) shown for
each cell line. Data are represented as the mean of triplicate wells ± SEM for each condition. b Growth of the indicated cell lines treated with
non-targeting control or MDM2 siRNA and cultured in SG-depleted medium for 7 days as in (a). c Western blot PSAT-1 and PSPH in the indicated
cell lines cultured in SG-depleted medium for 1 or 2 days. Note: this is a re-probe of the blot shown in Fig. 1f, where MDM2 and p21 levels are
shown. The ACTIN loading control blot is therefore the same in both figures. d Western blot for SSP enzymes PSAT-1, PSPH and PHGDH, and
MDM2 in the indicated cell lines treated with non-targeting control or MDM2 siRNA and grown in SG-depleted medium for 2 days. e Western
blot for HA-MDM2 in p53 KO cells transfected with an HA-tagged MDM2 expression construct (HA-MDM2) or a control vector containing GFP.
f Growth of p53 KO cells expressing HA-tagged MDM2 or a control vector (EV) and cultured in SG-depleted medium for 9 days. Data are
presented as mean ± SEM and depicted as iRFP intensity relative to the initial measurement obtained from triplicate wells per condition.
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Fig. 3 MDM2 supports redox robustness and interacts with ATF4 in R248W cells undergoing serine and glycine (SG) deprivation. a Oxidative
stress levels in the indicated cell lines treated with non-targeting control or MDM2 siRNA and cultured in SG-depleted or full medium for 3 days.
Median fluorescent intensity of the CellRox Green probe in triplicate samples is presented as mean ± SEM per condition. Data analysed using a
two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-adjusted p values. b Oxidative stress levels in the indicated cell
lines expressing HA-tagged MDM2 or a control vector (EV). c NADPH/NADP+ ratio in R248W cells with or without siRNA depletion of MDM2, or in
p53 null cells expressing HA-MDM2 or empty vector (EV), and cultured in SG-depleted or full medium for 3 days. The NADPH/NADP+ ratio is
shown as mean ± SEM from triplicate wells per condition. Data were analysed using a two-way ANOVA with Holm-Sidak’s multiple comparisons
test and multiplicity-adjusted p values. d IP and Western blot of the indicated cell lines cultured in SG-depleted or full medium for 24 h. ATF4 was
immunoprecipitated from each sample, then the imunoprecipitate (IP) or input lysate probed by Western blot for MDM2 and ATF4. e Oxidative
stress levels in R248W cells treated with non-targeting control, MDM2, or ATF4 siRNA as in (a). f Total NADPH and NADP+ pools in R248W cells
treated with non-targeting control (NT), MDM2, or ATF4 siRNA as in (c). BLQ: metabolite peak below quantitation/detection limit in
the experiment. Stars indicate statistical significance.
Humpton et al. Cancer & Metabolism            (2018) 6:18 Page 8 of 12
Humpton et al. Cancer & Metabolism            (2018) 6:18 Page 9 of 12starved conditions (Fig. 3c). This advantage was elimi-
nated in R248W cells following depletion of MDM2
(Fig. 3c), while ectopic expression of MDM2 in p53 null
cells resulted in a recovery of the NADPH/NADP+ ratio
(Fig. 3c). Interestingly, we detected a substantial increase
in the formation of an MDM2/ATF4 complex in R248W
cells undergoing serine and glycine starvation, which
was not detected in R175H-expressing cells (Fig. 3d).
Building on these findings, we sought to establish the
importance of ATF4 for the redox response of R248W
cells. We observed increased ROS levels and a greatly di-
minished NADPH/NADP+ ratio during serine and gly-
cine deprivation of R248W cells depleted of ATF4
(Fig. 3e, f ). Interestingly, while depletion of MDM2 did
not affect ROS levels or NADPH/NADP+ ratios in
R248W cells under fully fed conditions (Fig. 3a, c, e),
ATF4 function was required to limit ROS under both
fully fed and serine and glycine starved conditions
(Fig. 3e). Taken together, these findings suggest that en-
hanced redox robustness, facilitated in part by increasing
the previously published interaction between ATF4 and
MDM2 [14], helps to support proliferation in R248W cells
under serine and glycine starvation.
Our results show that in cultured cells, the R248W
mutant functions like wild-type p53 in supporting cells
during serine and glycine starvation. To understand the
implication of these observations in vivo, we carried out
xenograft studies using R175H and R248W cells, feeding
mice with a serine- and glycine-deficient diet [21]. As
seen previously with p53 null tumours, the growth of the
R175H tumours was retarded in mice on a serine- and
glycine-free diet (Fig. 4a and Additional file 1: Figure S3).
In contrast, R248W tumours grew equally well regardless
of the diet (Fig. 4a and Additional file 1: Figure S3). Im-
munohistochemical analysis recapitulated the observa-
tions in cells, confirming an increased expression of both
MDM2 and p21 in the R248W tumours compared to
R175H (Fig. 4b, c). Importantly, while R175H tumours
showed a clear increase in MDA staining, a marker of
lipid peroxidation and oxidative stress, this increase was
not seen in the R248W tumours in mice fed on a serine-
and glycine-free diet, which were able to sustain redox
balance (Fig. 4d, e).
Finally, we hypothesised that the in vitro and
in vivo redox advantages we uncovered for HCT116
R248W cells would translate into differences in hu-
man patient outcome based on p53 mutational status.
To assess this possibility, we utilised the publicly
available harmonised cancer datasets hosted on the
National Cancer Institute GDC data portal to com-
pare survival between patients with R248 mutations
to those with the R175H mutation. Based on this
analysis, we found that cases with tumours containing
R248 mutations had significantly shorter survival thanthose with tumours containing the R175H mutation
(median survival of 1481 days vs. 2483 days, Fig. 4f ).
These observations support a previous study showing
reduced survival of patients carrying R248 mutants
compared to patients with nonsense mutations [35].
Combined with our other observations, we speculate
that at least some of the accelerated lethality of R248
tumours can be explained by an enhanced redox
robustness and ability to respond to metabolic stress
conferred by the retention of pro-survival wild-type
p53 functions in p53 R248 mutant cells.
Discussion
While the selection for p53 point mutations in cancer
may reflect the loss of tumour suppressor properties and
acquisition of gain of oncogenic functions, it is also pos-
sible that some of these p53 mutants may contribute to
cancer development by the selective retention of wild-type
activities that promote cell survival. We show here that
one of the most common hotspot p53 mutants—
R248W—retains the ability of p53 wild-type cells to adapt
to serine and glycine starvation. This mutant has been as-
sociated with a gain of function reflecting the ability to in-
duce expression of drug metabolising enzymes [35] and
has also been shown to function in promoting survival of
cells undergoing glutamine starvation [15]. We show that
serine starvation also leads to the induction of p21 in
R248W-expressing cells, and while this may contribute to
the adaptation to serine starvation, it is not sufficient to
induce an anti-proliferative effect in our system.
MDM2 expression is required for cells to induce SSP
enzymes following serine starvation, but HCT116 cells did
not depend on a p53-driven increase in MDM2 levels to
support SSP activation. However, our study reveals a role
for p53-induced MDM2 in protecting cells under serine
starvation by ROS regulation. The increase in MDM2
levels seen in R248W p53 cells enhanced the formation of
a complex with ATF4 and the induction of an antioxidant
response that protected cells from the increase in ROS en-
countered during the switch to endogenous serine synthe-
sis [13]. Our results illustrate how different levels of
MDM2 are necessary for different functions—while very
low basal MDM2 levels are sufficient for activation of the
SSP, enhanced MDM2 expression that is dependent on
wild type or R248W p53 expression correlated with an
increase in binding to ATF4 and the induction of robust
antioxidant activity.
Clearly, the protective and adaptive functions of p53
can help to support tumour development under condi-
tions of nutrient deprivation. The R248W mutant com-
bines loss of cell elimination functions of wild-type p53
with the retention of the adaptive functions, so offering
maximum support for tumour development. Consist-
ently, we see that tumours expressing this mutant are
AB
C D
E F
Fig. 4 R248W mutant p53 confers enhanced tumour growth and increased ROS control in serine- and glycine (SG)-depleted conditions in vivo,
correlating with decreased human patient survival. a R175H or R248W tumour growth in SG or control fed mice. Data presented as iRFP level relative to
day 4 baseline reading (mean ± SEM) from N= 9 R175H control, N= 8 R175H − SG, N= 8 R248W control, and N= 10 R248W − SG tumours. Data analysed
using a two-way ANOVA with Tukey’s multiple comparisons test and multiplicity-adjusted p values. p value reported in figure from final measurements. b
H&E staining (× 40 magnification) and p21 and MDM2 IHC staining (× 20 magnification) in tumours from -SG fed mice. Representative images from at least
N= 5 tumours per group. c Quantification of p21 and MDM2 IHC staining in tumours from -SG fed mice. Each point represents the mean positive area
taken from seven random images per tumour. The black bar represents the mean value per group. N= 9 tumours per group for p21 IHC and N= 5
tumours per group for MDM2 IHC. Data analysed using a paired t test for each stain. d Malondialdehyde (MDA) IHC staining (× 20 magnification) in
tumours from control or − SG fed mice. Representative images shown from N= 5 tumours per group. e Quantification of MDA IHC staining in tumours
from control or − SG fed mice. Each point represents the mean positive area taken from seven random images per tumour. The black bar represents the
mean value per group of N= 5 tumours. Data were analysed using a two-way ANOVA with Holm-Sidak’s multiple comparisons test and multiplicity-
adjusted p values. f Survival curves for patients whose cancers contained R175H (N= 156 cases) or R248 (both W and Q pooled) (N= 207 cases). Median
survival (2483 days for R175H and 1481 days for R248) was compared between the groups using the Mantel-Cox Log-rank test
Humpton et al. Cancer & Metabolism            (2018) 6:18 Page 10 of 12
Humpton et al. Cancer & Metabolism            (2018) 6:18 Page 11 of 12not inhibited by a reduction in circulating serine and
glycine (in serine and glycine free diet fed mice) and
that expression of this mutant in human tumours is as-
sociated with a worse prognosis when compared to p53
null tumours. Several other p53 activities such as the
transient induction of autophagy and cell cycle arrest
also are likely to help cells adapt to limited exogenous
nutrient availability and may be retained by some
tumour-derived mutants. We therefore propose that the
selection for the expression of p53 point mutants could
reflect the retention of some wild-type p53 activity, as well
as the previously documented gain of function.
Conclusions
We show that the tumour-derived p53 R248W mutant
can support adaptation to serine starvation through the
activation of antioxidant defence pathways. This func-
tion reflects the selective retention of one arm of the
p53 response in concert with loss of the cell elimination
functions of the wild type protein. p53 mutants with this
activity give rise to more aggressive tumours that are re-
sistant to dietary serine modulation.
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